Breanna Nix's ‘American Idol' Consolation Prize: A Billboard No. 1
Breanna Nix's 'Higher' debuts at No. 1 on the Christian Digital Song Sales chart after her American ... More Idol season 23 third-place finish. AMERICAN IDOL - "818 (Disney Night #2)" "Disney Night" continues with heroes, villains and a special appearance by Lin-Manuel Miranda. The Top 5 travel to Disneyland Resort and perform twice as America votes live for the three heading to the finale. MONDAY, MAY 12 (8:00-10:01 p.m. EDT) on ABC. (Disney/Christopher Willard) BREANNA NIX (Photo by Christopher Willard/Disney via Getty Images)
The latest season of American Idol, which concluded on May 18, was one of the most exciting in recent memory. Several of the top contestants ended up releasing tracks that immediately became bestselling hits following the show's conclusion. Some years, only the winner manages to make any impact on the Billboard charts — and there have been times when even that doesn't happen. Season 23 was so chock-full of talent that even the singer who came in third place has managed to reach No. 1 on a chart in the United States.
Breanna Nix finished in third this season, ending up behind runner-up John Foster and ultimate winner Jamal Roberts. While she didn't take the crown, Nix does reach a number of Billboard rankings with her solo single "Higher," which has become a strong seller and demonstrates that — even without a win — there may be a market for her voice following the conclusion of the show.
"Higher" debuts at No. 1 on the Christian Digital Song Sales chart this week. It marks Nix's first leader on a Billboard tally. The tune replaces "Hard Fought Hallelujah" by Brandon Lake, which has turned out to be not just a winner on the Christian charts, but also a crossover success — one that has placed on Billboard's rock rankings and risen high on the Hot 100 as well.
Nix's tune sold well enough to reach not just the Christian Digital Song Sales chart, but also the all-genre Digital Song Sales ranking. On that roster, it opens at No. 4, thanks to a little under 4,700 pure purchases (per Luminate).
Sales powered "Higher" onto one of Billboard's consumption-based rankings as well. The tune lands at No. 40 on the Hot Christian Songs ranking, which lists the most popular tracks in that style by blending pure purchases, streaming activity, and radio airplay. Since she's a brand new artist with minimal promotional might, it seems that sales are largely to thank for "Higher" becoming a top 40 hit on the Christian-only tally.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
‘Lilo & Stitch' Box Office Mayhem: All the Records Broken as Pic Zooms Past $400M Globally
Talk about threading the needle perfectly. A week ago, no one could have imagined that Disney's live-action reimagining Lilo & Stitch would make box office history and open to a record-breaking $182.6 million during the four-day Memorial Day weekend, including $146 million for the three days. Overseas, the live-action redux of the 2002 animated film about a Hawaiian girl and mischievous, dog-like alien also exceeded all expectations in starting off with $178.6 million for a global start of $361.2 million against a net budget of $100 million. More from The Hollywood Reporter 'Lilo & Stitch' Sews Up Record $182.7M at Memorial Day Box Office, 'Mission: Impossible' Nabs Series-Best $79M Christopher McQuarrie Says He's Cracked the Story for 'Top Gun 3': "It's Already in the Bag" 'Lilo & Stitch' Blows Up Memorial Day Box Office With $183M Bow, 'Mission: Impossible' Nabs Series-Best $77.5M The pic is adding another milestone to its list today as it crosses the $400 million mark globally, including $200 million domestically in its sixth day in release — more than the total lifetime runs of some live-action Disney reimaginings. It's already out-grossed the entire $273.1 million global of run of 2002's animated Lilo & Stitch, not adjusted for inflation. To boot, it's pacing ahead of Warner Bros.' blockbuster A Minecraft Movie, at least in North America. In its sixth day in release, Minecraft had earned $193.2 million domestically. One would be hard-pressed to find another movie like Lilo & Stitch. Three weeks ahead of its release, it was tracking to open to $120 million domestically. A week later, it was a $145 million, followed by $165 million on the eve of the film's May 23 U.S. debut. Almost no one can think of a similar title popping like that, perhaps because few realized that Lilo & Stitch isn't just a kids film. Non-families made up 57 percent of the opening weekend audience, underscoring that the property is hallowed IP for Gen Zers and younger millennials, or 'zillennials.' When a PG-rated family film can attract general audiences, it's a recipe for magic. A Minecraft Movie, the top-grossing movie of the year to date, is another example. Ditto for A Super Mario Bros. Movie and Wicked, or Disney's Aladdin. Below are the records and other notable feats Lilo & Stitch has achieved, not adjusted for inflation. Tom Cruise knew there was no way Mission: Impossible was going to beat Lilo & Stitch, but he likely didn't expect an adorable alien creature to unseat his 2022 feature Top Gun: Maverick ($160.5 million) as the biggest Memorial Day opener of all time. Other top Memorial Day earners include Pirates of the Caribbean: At World's End ($139.8 million), Indiana Jones and the Kingdom of the Crystal Skull ($127 million) and X-Men: The Last Stand ($122.9 million). In North America, Lilo also boasts the second-biggest gross of all time for any four-day holiday weekend, behind the $242 million historic opening of Ryan Coogler's Black Panther over Presidents Day weekend in 2018. The top Martin Luther King Jr. holiday opening belongs to 2020's Bad Boys for Life ($73 million), while 2021's Shang-Chi and the Legend of the Ten Rings is the Labor Day crown holder ($94.7 million). The only two titles to open higher were 2019's The Lion King, which remains ruler of the pride with a $192 million start domestic start, followed by 2017's Beauty and the Beast with $175 million domestically. Again, it's the three-day number that determines the order. Without that industry rule, Lilo would be the second-biggest opening ever for a Disney live-action pic. Either way, it is only the fifth live-action reimagining to open to north of $100 million domestically. The other two were 2010's Alice in Wonderland ($116.1 million) and 2016's The Jungle Book ($103.3 million). And globally, Lilo has already out-grossed the entire runs of 2025 debacle Snow White ($204.2 million), 2016's Alice Through the Looking Glass ($299.5 million) and 2019's Dumbo ($353.3 million). On Memorial Day, Lilo & Stitch delivered one of the biggest grosses of all time for a Monday, with $36.6 million in ticket sales. That puts the movie in rarefied air, considering the top earners are 2018's Black Panther ($40.2 million), 2015's Star Wars: The Force Awakens ($40.1 million), 2021's Spider-Man: No Way Home ($37.1 million) and 2019's Avengers: Endgame ($36.9 million). Lilo took the spot previously held by Top Gun: Maverick ($33.8 million). Since box office openings officially are ranked by the three-day weekend number, Minecraft still sports the top domestic start of the year to date. Lilo's three-day gross was $146 million. A Minecraft Movie, which debuted to $162 million, presently sits at $940.7 million globally. It's unlikely to become the first Hollywood title of 2025 to join the $1 billion box office club. Could that be a feat for Lilo & Stitch? Lilo & Stitch wowed across Latin America to seize the highest opening ever for a Disney live-action remake. Mexico led all markets with $27 million, while the third top market was Brazil with $12.2 million. Europe was also strong, where the U.K. led with $17 million. It's overall international start of $178.6 million is the fourth-biggest ever for Disney live-action. Not bad. Lilo & Stitch joins the top 10 list of biggest openings for a PG title. Disney's film empire lays claim to eight of those, led by The Lion King, 2018's Incredibles 2 ($182.7 million) and Beauty and the Beast. Warners' Minecraft movie follows in fourth place. Then it's back to Disney with 2024's Inside Out 2 ($154.2 million), and followed by Universal's 2023 hit The Super Mario Bros. Movie ($146.6 million). Next up is Lilo with $146 million, followed three other Disney releases: 2024's Moana 2 ($140 million), 2016's Finding Dory ($135 million) and 2019's Frozen II ($130 million). Disney's live-action redo and Tom Cruise's final Mission: Impossible movie fueled the biggest start-of-summer holiday weekend of all time. Combined ticket sales for all films cleared nearly $330 million. The previous best Memorial Day frame in terms of overall revenue belonged to the $306 million in ticket sales collected in 2013 when Fast & Furious 6 zoomed to $117 million, followed by The Hangover Part III with $50 million. Best of The Hollywood Reporter 13 of Tom Cruise's Most Jaw-Dropping Stunts Hollywood Stars Who Are One Award Away From an EGOT 'The Goonies' Cast, Then and Now
The Hill
40 minutes ago
- The Hill
Puerto Rico is Trump's perfect partner in reshoring
President Trump recently signed an executive order to bring pharmaceutical manufacturing back to the U.S. by streamlining the process for the Food and Drug Administration to approve pharmaceutical manufacturing plants. This is the latest in the Trump administration's agenda to protect national security and create American jobs by promoting the reshoring of critical supply chains that Americans rely on every day. These efforts are coupled with international tariffs to encourage domestic manufacturing. Reshoring pharmaceutical manufacturing is not only dire for American national security, but it could have resounding economic impacts across the country. One U.S. jurisdiction that is ready and in a perfect position to partner in this effort is Puerto Rico, where pharmaceutical manufacturing is already a more than $50 billion industry. With complementary efforts underway in Congress and on the island, the White House should look to Puerto Rico as America's pharmaceutical powerhouse while not trapping the island in its current territory status by hindering a future transition to statehood that would further boost the island's manufacturing ability. As a territory, the island is part of the U.S. customs zone and is not subject to U.S. tariffs, and everything that is made in Puerto Rico is 'Made in the USA.' Yet, that same territory status has limited Puerto Rico's economic development by creating persistent uncertainty, underinvestment and an unequal playing field for economic competition. The territory status is unpopular on the island, and Puerto Rican voters have voted in favor of statehood four consecutive times, most recently last November. Trump and Congress have the opportunity of a generation to leverage the pharmaceutical infrastructure and workforce in Puerto Rico to achieve their agenda while also turbocharging the economy on the island, and they have the perfect ally in Puerto Rico to do it with — the island's Republican Gov. Jenniffer González-Colón. González-Colón is leading an ambitious agenda to reshape the national narrative about the island and its people — and ultimately achieve statehood for Puerto Rico. Aligning with the Trump administration's vision to reshore advanced manufacturing of critical products, she issued an executive order in late March and reached out to top White House officials to offer Puerto Rico's well-established, yet currently underutilized, manufacturing capacity as an economic engine to help grow American prosperity. González-Colón's executive order promotes the relocation of overseas manufacturing of pharmaceuticals and other products to Puerto Rico. Much like Trump's executive order, it eliminates barriers and streamlines the process for businesses to move to the island. This action is complementary to the Medical Manufacturing, Economic Development and Sustainability Act, which was recently reintroduced and incentivizes pharmaceutical manufacturing on the island and throughout economically distressed zones across the United States. The bill is designed to attract business to the island in a way that invests in the people of Puerto Rico. It does this by providing an incentive for medical manufacturing facilities to relocate to economically distressed zones, with an incentive dependent on the number of jobs created to ensure money is flowing back into communities. The incentive itself is based on economic factors and applies to communities throughout the United States — an appropriately wide scope that comports with Trump's strong desire to reshore large amounts of production in a short time frame. By tethering the tax credits to what manufacturers invest directly into wages, salaries and real middle-class benefits, the proposal creates good-paying, quality American jobs. Reshoring to Puerto Rico would mean that critical pharmaceuticals and medical devices, as well as other products that are currently manufactured overseas in China and other nations, would now be produced in America. This would create thousands of well-paying manufacturing jobs that Puerto Rico needs to turbocharge the modest economic progress it's made in recent years. The increased consumer demand on the island would help boost the approximately $70 billion in annual interstate commerce, resulting in more jobs and profits stateside. Puerto Rico is a natural partner in reshoring the medical and pharmaceutical manufacturing industry within U.S. borders. The island's leaders share in the White House's vision of a more prosperous pharmaceutical manufacturing industry and are working to ensure reshoring efforts do not trap Puerto Rico in its current territory status but instead enable it to reach its full potential as an engine of economic growth and prosperity as a future state of our Union. Manufacturing makes America stronger, especially when it lifts up communities and the hard-working American citizens that make 'Made in the USA' a possibility, including those in Puerto Rico.
Yahoo
an hour ago
- Yahoo
Cooper Companies Second Quarter 2025 Earnings: EPS Misses Expectations
Revenue: US$1.00b (up 6.3% from 2Q 2024). Net income: US$87.7m (down 1.3% from 2Q 2024). Profit margin: 8.7% (down from 9.4% in 2Q 2024). The decrease in margin was driven by higher expenses. EPS: US$0.44 (down from US$0.45 in 2Q 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 39%. Looking ahead, revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Performance of the American Medical Equipment industry. The company's shares are down 13% from a week ago. While earnings are important, another area to consider is the balance sheet. See our latest analysis on Cooper Companies' balance sheet health. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
